Brief: Ryvu Therapeutics Says SEL24/MEN1703 Administered To First Patient In Europe

Ryvu Therapeutics SA

16/09/2020 08:35

Sept 16 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAYS MENARINI RICERCHE WITH WHICH COMPANY HAS LICENCE
DEAL, HAS
GIVEN SEL24/MEN1703 TO FIRST PATIENT IN EUROPE UNDER II PHASE
CLINICAL TRIALS OF  DIAMOND-01
    * II PHASE CLINICAL TRIALS OF DIAMOND-01 ARE CONDUCTED IN
PATIENTS
WITH ACUTE MYELOID LEUKEMIA

Source text for Eikon:  ID:nEM9j21Dva 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))